Sunlenca(lenacapavir sodium)
Sunlenca (lenacapavir sodium) is a small molecule pharmaceutical. Lenacapavir sodium was first approved as Sunlenca on 2022-08-17. It is used to treat hiv-1 in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Sunlenca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lenacapavir sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUNLENCA | Gilead Sciences | N-215973 RX | 2022-12-22 | 1 products, RLD, RS |
| SUNLENCA | Gilead Sciences | N-215974 RX | 2022-12-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sunlenca | New Drug Application | 2024-07-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv-1 | — | D015497 | — |
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LENACAPAVIR SODIUM, SUNLENCA, GILEAD SCIENCES INC | |||
| 2027-12-22 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 9 | 6 | — | 1 | 15 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 3 | — | — | 5 |
| Communicable diseases | D003141 | — | — | 1 | 2 | 3 | — | — | 5 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 2 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lenacapavir sodium |
| INN | lenacapavir |
| Description | Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.
|
| Classification | Small molecule |
| Drug class | antivirals: viral capsid inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c([N-]S(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O.[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 2283356-12-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4802249 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15673 |
| UNII ID | A9A0O6FB4H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
135 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use